TEAMLEUKEMIA – TREATMENT EVOLUTION ON ACUTE MYELOID LEUKEMIA GRUPPO DI LAVORO IN TEMA: MONITORAGGIO DELLA RISPOSTA NELLE TERAPIE CON I NUOVI AGENTI

1. 1.Massimo Breccia et al.. Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network. Clin Lymphoma Myeloma Leuk . 2025 Jan;25(1):e34-e39. doi: 10.1016/j.clml.2024.08.009. Epub 2024 Sep 7.. 2025
   Articolo scientificoClin Lymphoma Myeloma Leuk . 2025 Jan;25(1):e34-e39. doi: 10.1016/j.clml.2024.08.009. Epub 2024 Sep 7.Leggi il PDF gratuito
2. 2.Jacopo Nanni et al.. Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting. Observational Study Cancer . 2025 Apr 1;131(7):e35824. doi: 10.1002/cncr.35824.. 2025
   Articolo scientificoObservational Study Cancer . 2025 Apr 1;131(7):e35824. doi: 10.1002/cncr.35824.Leggi il PDF gratuito
3. 3.Adriano Venditti et al.. Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. 2025
   Articolo scientificoFitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetCerca su Google Scholar

I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).